Key Facts
• Japanese pharmaceutical firms limit responses to U.S. drug tariffs to short-term measures.
• U.S.-Japan agreement ensures Japan is not treated less favorably than other nations.
• Former President Trump proposed raising drug tariffs to 250%, increasing uncertainty.
• Pharmaceutical supply chains are complex, making rapid adjustments challenging.
• Astellas Pharma CFO Jun Kitamura emphasizes internal discussions for long-term strategies.
• Daiichi Sankyo CFO Koji Ogawa reports limited impact on cancer drug “Enhertu” due to inventory adjustments.
• U.S.-based production, such as Kyowa Kirin’s North Carolina facility (operational by 2027), is a potential solution.
• Kyowa Kirin considers manufacturing active ingredients domestically to mitigate tariff impacts.
• Companies await clarity on tariff rates, targets, and implementation timelines.
Summary
Japanese pharmaceutical companies are grappling with the uncertainty surrounding U.S. drug tariffs, with short-term measures like inventory adjustments being the primary response. Despite assurances from a U.S.-Japan agreement, the potential for a 250% tariff hike underlines the challenges. Complex supply chains hinder rapid adaptation, prompting firms like Astellas Pharma and Daiichi Sankyo to focus on internal discussions and scenario planning. Meanwhile, Kyowa Kirin explores U.S.-based production, including a new North Carolina facility set to open in 2027, as a long-term solution. The industry remains watchful for further details on tariff policies to determine next steps.
